Sun Pharmaceutical vs Zydus Lifesciences: share price, P/E, ROE and financials compared
Sun Pharmaceutical Industries
Zydus Lifesciences
Sun Pharmaceutical and Zydus Lifesciences at a glance
Sun Pharmaceutical and Zydus Lifesciences are both listed in Healthcare. Sun Pharmaceutical is the larger by market cap, at ₹4.5L Cr against ₹1.2L Cr for Zydus Lifesciences (3.7 times as large). On valuation, Zydus Lifesciences has the lower P/E (28.6× against 40.7×) and the lower price-to-book (4.29× against 4.99×). On returns and margins, Sun Pharmaceutical has the higher operating margin (28.2% against 26.2%), while Zydus Lifesciences has the higher ROCE (19.0% against 17.9%) and the higher ROE (14.7% against 13.1%). Over three years, Zydus Lifesciences has faster 3-year sales growth (+16.5% against +10.4% a year) and faster 3-year profit growth (+37.0% against +10.6% a year). Sun Pharmaceutical carries less debt for its equity, with a debt-to-equity of 0.04× against 0.46×.
Key metrics, side by side
| Metric | Sun PharmaceuticalSUNPHARMA | Zydus LifesciencesZYDUSLIFE |
|---|---|---|
| Price (₹) | 1,860.00 | 1,197.90 |
| Market cap (₹ Cr) | 4,46,276 | 1,19,491 |
| P/E | 40.7× | 28.6× (the lower figure, shaded) |
| P/B | 4.99× | 4.29× (the lower figure, shaded) |
| Dividend yield, trailing | 0.86% (the higher figure, shaded) | 0.08% |
| ROE | 13.1% | 14.7% (the higher figure, shaded) |
| ROCE | 17.9% | 19.0% (the higher figure, shaded) |
| Operating margin (OPM) | 28.2% (the higher figure, shaded) | 26.2% |
| Net margin (NPM) | 17.8% (the higher figure, shaded) | 13.8% |
| Sales CAGR 3Y | +10.4% | +16.5% (the higher figure, shaded) |
| Profit CAGR 3Y | +10.6% | +37.0% (the higher figure, shaded) |
| Debt to equity | 0.04× (the lower figure, shaded) | 0.46× |
| Interest cover | 45.6× (the higher figure, shaded) | 19.1× |
| Net profit TTM (₹ Cr) | 10,966 | – |
| 1Y return | +8.2% | +22.8% (the higher figure, shaded) |
| Promoter holding | 52.68% | 75.01% |
Sun Pharmaceutical vs Zydus Lifesciences: common questions
Which is bigger, Sun Pharmaceutical or Zydus Lifesciences?
By market cap, Sun Pharmaceutical is bigger at ₹4.5L Cr, against ₹1.2L Cr for Zydus Lifesciences (prices as of 6 Nov 2026).
Which has a lower P/E ratio, Sun Pharmaceutical or Zydus Lifesciences?
Sun Pharmaceutical trades at a P/E of 40.7× and Zydus Lifesciences at 28.6×. Zydus Lifesciences has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Sun Pharmaceutical or Zydus Lifesciences?
Sun Pharmaceutical reports a return on equity of 13.1% and Zydus Lifesciences 14.7%. Zydus Lifesciences has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Sun Pharmaceutical or Zydus Lifesciences?
Over the last three years: Sales grew +10.4% a year at Sun Pharmaceutical and +16.5% at Zydus Lifesciences, so Zydus Lifesciences grew sales faster; profit grew +10.6% a year at Sun Pharmaceutical and +37.0% at Zydus Lifesciences, so Zydus Lifesciences grew profit faster. Past growth doesn’t predict future growth.